Preventing preeclampsia with aspirin: does dose or timing matter?

American Journal of Obstetrics and Gynecology

Volumn 216, Issue 2, 2017, Pages 95-97

  Tong, Stephen ^a   Mol, Ben W ^b   Walker, Susan P ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ESOMEPRAZOLE; HEPARIN; METFORMIN; PLACEBO; PRAVASTATIN; SILDENAFIL; ANTITHROMBOCYTIC AGENT;

DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; FETUS DEATH; FETUS HEART RATE; GESTATIONAL AGE; HUMAN; INTRAUTERINE GROWTH RETARDATION; META ANALYSIS (TOPIC); OBSTETRIC DELIVERY; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY TOXEMIA; PREMATURE LABOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SMALL FOR DATE INFANT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; FEMALE; PREGNANCY;

ASPIRIN; FEMALE; FETAL GROWTH RETARDATION; HUMANS; PLATELET AGGREGATION INHIBITORS; PRE-ECLAMPSIA; PREGNANCY;

EID: 85010876926     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2016.12.003     Document Type: Editorial

References (19)

1. 1 Goodlin, R.C., Haesslein, H.O., Fleming, J., Aspirin for the treatment of recurrent toxemia. Lancet, 2, 1978, 51.
2. 2 Bujold, E., Roberge, S., Lacasse, Y., et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 116 (2010), 402–414.
3. 3 Roberge, S., Nicolaides, K.H., Demers, S., Villa, P., Bujold, E., Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol 41 (2013), 491–499.
4. 4 Tranquilli, A.L., Dekker, G., Magee, L., et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens 4 (2014), 97–104.
5. 5 Magee, L.A., Pels, A., Helewa, M., Rey, E., von Dadelszen, P., SOGC Hypertension Guideline Committee. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can 36 (2014), 575–576.
6. 6 Roberge, S., Nicolaides, K., Demers, S., Hyett, J., Chaillet, N., Bujold, E., The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol 216 (2017), 110–120 e1-6.
7. 7 Meher, S., Duley, L., Hunter, K., Askie, L., Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol 216 (2017), 121–128.
8. 8 Askie, L.M., Duley, L., Henderson-Smart, D.J., Stewart, L.A., PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 369 (2007), 1791–1798.
9. 9 Riley, R.D., Lambert, P.C., Abo-Zaid, G., Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ, 340, 2010, c221.
10. 10 Merviel, P., Carbillon, L., Challier, J.C., Rabreau, M., Beaufils, M., Uzan, S., Pathophysiology of preeclampsia: links with implantation disorders. Eur J Obstet Gynecol Reprod Biol 115 (2004), 134–147.
11. 11 Vainio, M., Riutta, A., Koivisto, A.M., Maenpaa, J., Prostacyclin, thromboxane A and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders. Acta Obstet Gynecol Scand 83 (2004), 1119–1123.
12. 12 O'Gorman, N., Wright, D., Rolnik, D.L., Nicolaides, K.H., Poon, L.C., Study protocol for the randomized controlled trial: combined multimarker screening and randomized patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE). BMJ Open, 6, 2016, e011801.
13. 13 Institute of Medicine. Finding what works in health care: standards for systematic reviews. 2011, National Academies Press, Washington (DC).
14. 14 Moher, D., Shamseer, L., Clarke, M., et al., PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev, 4, 2015, 1.
15. 15 Trapani, A. Jr., Goncalves, L.F., Trapani, T.F., Vieira, S., Pires, M., Pires, M.M., Perinatal and hemodynamic evaluation of sildenafil citrate for preeclampsia treatment: a randomized controlled trial. Obstet Gynecol 128 (2016), 253–259.
16. 16 Cluver, C.A., Walker, S.P., Mol, B.W., et al. Double blind, randomized, placebo-controlled trial to evaluate the efficacy of esomeprazole to treat early onset pre-eclampsia (PIE trial): a study protocol. BMJ Open, 5, 2015, e008211.
17. 17 Brownfoot, F.C., Hastie, R., Hannan, N.J., et al. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstet Gynecol 214 (2016), 356.e1–356.e15.
18. 18 Brownfoot, F.C., Tong, S., Hannan, N.J., et al. Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia. Hypertension 66 (2015), 687–697.
19. 19 Costantine, M.M., Cleary, K., Hebert, M.F., et al., Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Units Network. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol 214 (2016), 720.e1–720.e17.